The urokinase receptor and integrins constitute a cell migration signalosome

The Cancer Degradome: Proteases and Cancer Biology

Volumn , Issue , 2008, Pages 451-474

  Degryse, Bernard ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80051701116     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69057-5_23     Document Type: Chapter

References (134)

1. Abu-Ali S., Sugiura T., Takahashi M., et al. (2005). Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells. J. Cell. Physiol. 203:410-419
2. Adachi Y., Lakka S. S., Chandrasekar N., et al. (2001). Down-regulation of integrin alpha(v)beta (3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J. Biol. Chem. 276:47171-47177
3. Aguirre Ghiso J. A., Kovalski K., and Ossowski L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147:89-104
4. Aguirre-Ghiso J. A., Liu D., Mignatti A., et al. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell. 12:863-879
5. Barinka C., Parry G., Callahan J., et al. (2006). Structural basis of interaction between urokinasetype plasminogen activator and its receptor. J. Mol. Biol. 363:482-495
6. Bass R., Werner F., Odintsova E., et al. (2005). Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J. Biol. Chem. 280:14811-14818
7. Besta F., Massberg S., Brand K., et al. (2002). Role of beta(3)-endonexin in the regulation of NFkappaB- dependent expression of urokinase-type plasminogen activator receptor. J. Cell Sci. 115:3879-3888
8. Bianchi E., Ferrero E., Fazioli F., et al. (1996). Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. Clin. Invest. 98:1133-1141
9. Blasi F. (1999). The urokinase receptor. A cell surface, regulated chemokine. APMIS 107:96-101
10. Blasi F. and Carmeliet P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol. 3:932-943
11. Bohuslav J., Horejsi V., Hansmann C., et al. (1995). Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1381-1390
12. Bru?ner N., Nielsen H. J., Hamers M., et al. (1999). The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS. 107:160-167
13. Cabodi S., Moro L., Bergatto E., et al. (2004). Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem. Soc. Trans. 32:438-442
14. Carriero M. V., Del Vecchio S., Capozzoli M., et al. (1999). Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59:5307-5314
15. Chapman H. A., Wei Y., Simon D. I., et al. (1999). Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb. Haemost. 82:291-297
16. Chaurasia P., Aguirre-Ghiso J. A., Liang O. D., et al. (2006). A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J. Biol. Chem. 281:14852-14863
17. Chavakis T., May A. E., Preissner K. T., et al. (1999). Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins. Blood 93:2976-2983
18. Chavakis T., Kanse S. M., Lupu F., et al. (2000). Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96:514-522
19. Chintala S. K., Mohanam S., Go Y., et al. (1997). Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Mol. Carcinog. 20:355-365
20. Ciambrone G. J. and McKeown-Longo P. J. (1992). Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J. Biol. Chem. 267:13617-13622
21. Colman R. W., Pixley R. A., Najamunnisa S., et al. (1997). Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 100:1481-1487
22. Conese M., Nykjaer A., Petersen C. M., et al. (1995). Alpha-2 macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131:1609-1622
23. Cunningham O., Andolfo A., Santovito M. L., et al. (2003). Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 22:5994-6003
24. Czekay R.-P., Kuemmel T. A., Orlando R. A., et al. (2001). Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell. 12:1467-1479
25. Czekay R.-P., Aertgeerts K., Curriden S. A., et al. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160:781-791
26. Degryse B. (2003). Is uPAR the centre of a sensing system involved in the regulation of inflammation? Curr. Med. Chem Anti-Inflammatory &Anti-Allergy Agents 2:237-259
27. Degryse B., Resnati M., Rabbani S. A., et al. (1999). Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood 94:649-662
28. Degryse B., Orlando S., Resnati M., et al. (2001a). Urokinase/urokinase receptor and vitronectin/ alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20:2032-2043
29. Degryse B., Sier C. F., Resnati M., et al. (2001b). PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505:249-254
30. Degryse B., Resnati M., Czekay R. -P., et al. (2005). Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280:24792-24803
31. Demetriou M. C., Pennington M. E., Nagle R. B., et al. (2004). Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp. Cell Res. 294:550-558
32. Dumler I., Weis A., Mayboroda O. A., et al. (1998). The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273:315-321
33. Dumler I., Kopmann A.,Weis A., et al. (1999a). Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19:290-297
34. Dumler I., Kopmann A., Wagner K., et al. (1999b). Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J. Biol. Chem. 274:24059-24065
35. Edwards S., Lalor P. F., Tuncer C., et al. (2006). Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br. J. Cancer 95:1545-1554
36. Ellis V., Scully M. F., and Kakkar V. V. (1989). Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264:2185-2188
37. Fazioli F., Resnati M., Sidenius N., et al. (1997). A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16:7279-7286
38. Ffrench-Constant C. and Colognato H. (2004). Integrins: versatile integrators of extracellular signals. Trends Cell Biol. 14:678-686
39. Franco P., Vocca I., Carriero M. V., et al. (2006). Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J. Cell Sci. 119:3424-3434
40. Furlan F., Orlando S., Laudanna C., et al. (2004). The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J. Cell Sci. 117:2909-2916
41. Galbraith C. G., Yamada K. M., and Galbraith J. A. (2007). Polymerizing actin fibers position integrins primed to probe for adhesion sites. Science 315:992-995
42. Gellert G. C., Goldfarb R. H., and Kitson R. P. (2004). Physical association of uPAR with the alphaV integrin on the surface of human NK cells. Biochem. Biophys. Res. Commun. 315:1025-1032
43. Ghosh S., Brown R., Jones J. C., et al. (2000). Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3beta 1 integrin in oral keratinocytes. J. Biol. Chem. 275:23869-23876
44. Ghosh S., Johnson J. J., Sen R., et al. (2006). Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J. Biol. Chem. 281:13021-13029
45. Giancotti F. G. and Tarone G. (2003). Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu. Rev. Cell Dev. Biol. 19:173-206
46. Ginsberg M. H., Partridge A., and Shattil S. J. (2005). Integrin regulation. Curr. Opin. Cell Biol. 17:509-516
47. Gondi C. S., Kandhukuri N., Kondraganti S., et al. (2006). Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation. Int. J. Oncol. 28:633-639
48. Hapke S., Gawaz M., Dehne K., et al. (2001a). beta(3)A-integrin downregulates the urokinasetype plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol. Cell. Biol. 21:2118-2132
49. Hapke S., Kessler H., Arroyo de Prada N., et al. (2001b). Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 276:26340-26348
50. Hehlgans S., Haase M., and Cordes N. (2007). Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775:163-180
51. Hoyer-Hansen G., Ronne E., Solberg H., et al. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267:18224-18229
52. Huai Q., Mazar A. P., Kuo A., et al. (2006). Structure of human urokinase plasminogen activator in complex with its receptor. Science 311:656-659
53. Huang M., Mazar A. P., Parry G., et al. (2005). Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). Acta Crystallogr. D Biol. Crystallogr. 61:697-700
54. Jin H., Song Y. P., Boel G., et al. (2005). Group A streptococcal surface GAPDH, SDH, recognizes uPAR/CD87 as its receptor on the human pharyngeal cell and mediates bacterial adherence to host cells. J. Mol. Biol. 350:27-41
55. Khatib A. M., Nip J., Fallavollita L., et al. (2001). Regulation of urokinase plasminogen activator/ plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. Int. J. Cancer 91:300-308
56. Kim K. S., Hong Y. K., Joe Y. A., et al. (2003a). Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem. 278:11449-11456
57. Kim K. S., Hong Y. K., Lee Y., et al. (2003b). Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp. Mol. Med. 35:578-585
58. Kim C. K., Hong S. H., Joe Y. A., et al. (2007). The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth. Cancer Sci. 98:253-258
59. Kinashi T. (2005). Intracellular signalling controlling integrin activation in lymphocytes. Nat. Rev. Immunol. 5:546-559
60. Kindzelskii A. L., Xue W., Todd R. F. 3rd., et al. (1994). Aberrant capping of membrane proteins on neutrophils from patients with leukocyte adhesion deficiency. Blood 83:1650-1655
61. Kindzelskii A. L., Eszes M. M., Todd R. F. 3rd., et al. (1997). Proximity oscillations of complement type 4 (alphaX beta2) and urokinase receptors on migrating neutrophils. Biophys. J. 73:1777-1784
62. Kjoller L. and Hall A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152:1145-1157
63. Koshelnick Y., Ehart M., Hufnagl P., et al. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272:28563-28567
64. Kwak S. H., Mitra S., Bdeir K., et al. (2005). The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V {beta}3 integrins. J. Leukoc. Biol. 78:937-945
65. Leksa V., Goda? S., Cebecauer M., et al. (2002). The N terminus of mannose 6-phosphate/insulinlike growth factor 2 receptor in regulation of fibrinolysis and cell migration. J. Biol. Chem. 277:40575-40582
66. Llinas P., Le Du M. H., Gardsvoll H., et al. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24:1655-1663
67. Liu D., Aguirre Ghiso J., Estrada Y., et al. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 1:445-457
68. Madsen C. D., Ferraris G. M., Andolfo A., et al. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 177:927-939
69. Margheri F., Manetti M., Serrati S., et al. (2006). Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 54:3926-3938
70. May A. E., Kanse S. M., Lund L. R., et al. (1998). Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 188:1029-1037
71. May A. E., Neumann F. J., Schomig A., et al. (2000). VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 96:506-513
72. May A. E., Schmidt R., Kanse S. M., et al. (2002). Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 100:3611-3617
73. Mazar A. P. (2001). The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12:387-400
74. Mazzieri R., DAlessio S., Kenmoe R. K., et al. (2006). An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17:367-378
75. Montuori N., Rossi G., and Ragno P. (1999). Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett. 460:32-36
76. Montuori N., Carriero M. V., Salzano S., et al. (2002). The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 277:46932-46939
77. Myohanen H. T., Stephens R. W., Hedman K., et al. (1993). Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 41:1291-1301
78. Naldini L., Tamagnone L., Vigna E., et al. (1992). Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11:4825-4833
79. Naldini L., Vigna E., Bardelli A., et al. (1995). Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J. Biol. Chem. 270:603-611
80. Nguyen D. H., Catling A. D., Webb D. J., et al. (1999). Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activatorstimulated cells in an integrin-selective manner. J. Cell Biol. 146:149-164
81. Nip J., Rabbani S. A., Shibata H. R., et al. (1995). Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J. Clin. Invest. 95:2096-2103
82. Nykjaer A., Petersen C. M., Moller B., et al. (1992). Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase. plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 267:14543-14546
83. Nykjaer A., Kjoller L., Cohen R. L., et al. (1994). Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J. Biol. Chem. 269:25668-25676
84. Nykjaer A., Conese M., Christensen E. I., et al. (1997). Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16:2610-2620
85. Nykjaer A., Christensen E. I., Vorum H., et al. (1998). Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol. 141:815-828
86. Odekon L. E., Sato Y., and Rifkin D. B. (1992). Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell Physiol. 150:258-263
87. Odekon L. E., Blasi F., and Rifkin D. B. (1994). Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J. Cell Physiol. 158:398-407
88. Pawar S. C., Demetriou M. C., Nagle R. B., et al. (2007). Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp. Cell Res. 313:1080-1089
89. Ploug M. and Ellis V. (1994). Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 349:163-168
90. Pluskota E., Soloviev D. A., and Plow E. F. (2003). Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101:1582-1590
91. Pluskota E., Soloviev D. A., Bdeir K., et al. (2004). Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J. Biol. Chem. 279:18063-18072
92. Pollanen J., Hedman K., Nielsen L. S., et al. (1988). Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol. 106:87-95
93. Porter J. C. and Hogg N. (1998). Integrins take partners: cross-talk between integrins and other membrane receptors. Trends Cell Biol. 8:390-396
94. Ragno P. (2006). The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell. Mol. Life Sci. 63:1028-1037
95. Ragno P., Montuori N., Covelli B., et al. (1998). Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res. 58:1315-1319
96. Reinartz J., Schafer B., Batrla R., et al. (1995). Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp. Cell Res. 220:274-282
97. Resnati M., Guttinger M., Valcamonica S., et al. (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15:1572-1582
98. Resnati M., Pallavicini I., Wang J. M., et al. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99:1359-1364
99. Roztocil E., Nicholl S. M., and Davies M. G. (2007). Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration. J. Surg. Res. 141:83-90
100. Sawai H., Okada Y., Funahashi H., et al. (2006). Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol. 7:8
101. Schwab W., Gavlik J. M., Beichler T., et al. (2001). Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1- integrin. Histochem. Cell Biol. 115:317-323
102. Sidenius N. and Blasi F. (2000). Domain 1 of the urokinase receptor (uPAR) is required for uPARmediated cell binding to vitronectin. FEBS Lett. 470:40-46
103. Sidenius N., Andolfo A., Fesce R., et al. (2002). Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277:27982-27990
104. Sier C. F., Sidenius N., Mariani A., et al. (1999). Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab. Invest. 79:717-722
105. Silvestri I., Longanesi Cattani I., Franco P., et al. (2002). Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression. Int. J. Cancer 102:562-571
106. Simon D. I., Rao N. K., Xu H., et al. (1996). Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88:3185-3194
107. Simon D. I., Wei Y., Zhang L., et al. (2000). Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 275:10228-10234
108. Simons K. and Toomre D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1:31-39
109. Sitrin R. G., Todd R. F. 3rd., Albrecht E., et al. (1996). The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest. 97:1942-1951
110. Sitrin R. G., Pan P. M., Harper H. A., et al. (1999). Urokinase receptor (CD87) aggregation triggers phosphoinositide hydrolysis and intracellular calcium mobilization in mononuclear phagocytes. J. Immunol. 163:6193-6200
111. Sitrin R. G., Pan P. M., Harper H. A., et al. (2000). Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J. Immunol. 165:3341-3349
112. Stahl A. and Mueller B. M. (1995). The urokinase-type plasminogen activator receptor, a GPIlinked protein, is localized in caveolae. J. Cell Biol. 129:335-344
113. Stahl A. and Mueller B. M. (1997). Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int. J. Cancer 71:116-122
114. Stefansson S. and Lawrence D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin. Nature 383:441-443
115. Stepanova V., Jerke U., Sagach V., et al. (2002). Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2. J. Biol. Chem. 277:10265-10272
116. Stephens R. W., Nielsen H. J., Christensen I. J., et al. (1999). Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst. 91:869-874
117. Tarui T., Mazar A. P., Cines D. B., et al. (2001a). Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J. Biol. Chem. 276:3983-3990
118. Tarui T., Miles L. A., and Takada Y. (2001b). Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem. 276:39562-39568
119. Tarui T., Akakura N., Majumdar M., et al. (2006). Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost. 95:524-534
120. Wang G. J., Collinge M., Blasi F., et al. (1998). Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc. Natl. Acad. Sci. USA. 95:6296-6301
121. Weaver A. M., Hussaini I. M., Mazar A., et al. (1997). Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J. Biol. Chem. 272:14372-14379
122. Webb D. J., Nguyen D. H., Sankovic M., et al. (1999). The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274:7412-7420
123. Webb D. J., Nguyen D. H., and Gonias S. L. (2000). Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J. Cell Sci. 113:123-134
124. Wei Y., Lukashev M., Simon D. I., et al. (1996). Regulation of integrin function by the urokinase receptor. Science 273:1551-1555
125. Wei Y., Yang X., Liu Q., et al. (1999). A role for caveolin and the urokinase receptor in integrinmediated adhesion and signaling. J. Cell Biol. 144:1285-1294
126. Wei Y., Eble J. A., Wang Z., et al. (2001). Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12:2975-2986
127. Wei Y., Czekay R. P., Robillard L., et al. (2005). Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168:501-511
128. Wei Y., Tang C. H., Kim Y., et al. (2007). Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 282:3929-3939
129. Wong W. S., Simon D. I., Rosoff P. M., et al. (1996). Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). Immunology. 88:90-97
130. Xia Y., Borland G., Huang J., et al. (2002). Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion. J. Immunol. 169:6417-6426
131. Xue W., Kindzelskii A. L., Todd R. F. 3rd., et al. (1994). Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 152:4630-4640
132. Xue W., Mizukami I., Todd R. F., et al. (1997). Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57:1682-1689
133. Yebra M., Parry G. C., Stromblad S., et al. (1996). Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. 271:29393-29399
134. Yebra M., Goretzki L., Pfeifer M., et al. (1999). Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp. Cell Res. 250:231-240.